SEC Form 4 · accession 0001171843-16-011435
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon N. Pimstone
Officer — President & CEO · Director
Period of report
Jul 29, 2016
Accepted (ET)
Aug 2, 2016 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jul 29, 2016 | M | 12,345 | $3.30 | A | 216,550 | D | |
| Common SharesF2 | Jul 29, 2016 | F | 4,703 | $7.46 | D | 211,847 | D | |
| Common Shares | holding | — | — | — | 16,460 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $3.30 | Jul 29, 2016 | M | 12,345 | D | — | Jul 31, 2016 | Common Shares | 12,345 | 0 | D |
Explanation of responses
- F1The exercise price was converted from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares on July 28, 2016, converted to a Canadian dollar amount for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on August 1, 2010.